 |
111 Diseases |  |
73 Trials |
|
73 Trials |  |
1509 News |  |
| «12...4567891011121314...3637» |
- galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
TREATMENT STATUS OF ALZHEIMER’S DEMENTIA USING COMMON DATA MODEL IN SOUTH KOREA. () - Oct 5, 2022 - Abstract #CTAD2022CTAD_181;
There were differences in persistence and the prescribing pattern among anti-dementia medications from database using the Observational Medical Outcome Partnership Common Data Model in South Korea.
- solanezumab (LY2062430) / Eli Lilly
IMPACT OF DISEASE PROGRESSION ON DEPENDENCY IN PATIENTS WITH MILD AND MODERATE ALZHEIMER DISEASE. () - Oct 5, 2022 - Abstract #CTAD2022CTAD_133;
P3
Treatments that slow disease progression in early symptomatic AD have the potential to delay patients’ need for more extensive home care or assisted living seen in moderate AD. Full COI disclosure will be on the 2nd slide of the presentation or in the poster presentation.
- memantine / Generic mfg.
SLOWING OF ALZHEIMER'S DISEASE PROGRESSION WITH NEUROAID. () - Oct 5, 2022 - Abstract #CTAD2022CTAD_130;
P2
The treatment effect was most substantial at M12 in patients who were compliant to the study medication and study completers, as shown in PP analysis. The previously available preclinical and clinical data, along with the recent promising ATHENE study results suggest that the next step in the clinical development of MLC901 in AD should be to design a larger clinical study of a longer duration with added biomarkers to demonstrate a disease modification effect in AD.
- Aduhelm (aducanumab) / Eisai, Biogen, ASD-005 / Asdera
BEYOND TARGETING AB AND TAU: NOVEL FORMULATIONS OF ALPHA-CYCLODEXTRINS FOR THE SAFE (NOT OTOTOXIC) AND CONVENIENT (ORAL) PREVENTION AND TREATMENT OF ALZHEIMER’S DISEASE. () - Oct 5, 2022 - Abstract #CTAD2022CTAD_53;
For instance, an official name of “ABCA1, a membrane cholesterol transporter” (Yao J, 2012, J Exp Med 209: 2501) is “Phospholipid-Transporting ATPase” (genecards). Unfortunately, HPβCD also causes cholesterolrelated permanent hearing loss.
- | memantine / Generic mfg.
Preclinical, Journal: Neuroprotective effects of combined therapy with memantine, donepezil, and vitamin D in ovariectomized female mice subjected to dementia model. (Pubmed Central) - Oct 5, 2022
Notably, triple-association treatment reversed the effects of the exposition of mice to Aβ and OVX in the long-term spatial and habituation memories impairment, as well as reversed changes in TNFα, IL-1β, IL-4, and GFAP immunoreactivity levels in the hippocampus of treated animals. Our results indicate that the therapeutic association of vitamin D, memantine, and donepezil has beneficial effects on memory performance and attenuated the neuroinflammatory response in female mice subjected to OVX associated with a dementia animal model.
- | memantine / Generic mfg.
Preclinical, Journal: Anxiogenic and anxiolytic effects of memantine injected into the ventral hippocampus in male stressed mice. (Pubmed Central) - Oct 4, 2022
Our results indicate that the therapeutic association of vitamin D, memantine, and donepezil has beneficial effects on memory performance and attenuated the neuroinflammatory response in female mice subjected to OVX associated with a dementia animal model. It could be concluded that NMDA glutamate receptors in the ventral hippocampus may play a pivotal role in the mediation of maintenance of anxiety and depression induced by stress in the mice.
- | Journal: Forskolin, an Adenylcyclase/cAMP/CREB Signaling Activator Restoring Myelin-Associated Oligodendrocyte Destruction in Experimental Ethidium Bromide Model of Multiple Sclerosis. (Pubmed Central) - Oct 1, 2022
The Luxol fast blue (LFB) stain results further indicate FSK's neuroprotective potential in preventing oligodendrocyte death. Therefore, the results of these studies contribute to a better understanding of the possible role that natural phytochemicals FSK could have in preventing motor neuron diseases, such as multiple sclerosis.
- memantine / Generic mfg.
PREVENTIVE MEMANTINE TREATMENT FOR THE COMORBIDITY OF STROKE AND ALZHEIMER'S DISEASE (Room 332) - Oct 1, 2022 - Abstract #WSC2022WSC_210;
This investigation demonstrates the dual benefits of the clinical drug MEM in AD mouse models before and after ischemic stroke. The early MEM preventive therapy is a mechanism-based treatment for people susceptible to AD and stroke.
- || memantine / Generic mfg.
Probably better off just finding some amandatine and memantine. Will be years before anything actually happens, no doubt. https://t.co/pdGbxowbO3 (Twitter) - Sep 30, 2022
- | Cognex (tacrine) / Shionogi
Journal: Incidence of dementia in patients with rheumatoid arthritis and association with disease modifying anti-rheumatic drugs - Analysis of a national claims database. (Pubmed Central) - Sep 30, 2022
The incidence of dementia in patients with RA was lower in patients receiving b/tsDMARDs when compared to patients on csDMARD only. No differences were observed between different classes of b/tsDMARDs, suggesting that decreased risk is possibly explained by the overall decrease in inflammation rather than a specific mechanism of action of these drugs.
- memantine / Generic mfg.
Memantine increases dendritic arborization of immature neurons after irradiation with no evidence of disruption in the normal brain function (West/Central Hall) - Sep 28, 2022 - Abstract #SNO2022SNO_1066;
At six weeks after IR, Mem treatment maintains the gamma oscillatory dynamics in the hippocampal CA3 region (~2x10-9 V2 in non-IR, ~1x109 V2 in IR), but with no apparent recovery to the sham levels. These results emphasize the strong neurogenic effect that Mem exerts on the surviving newborn neurons, while also highlighting Mem's low toxicity and impact on the normal function of the brain.
- memantine / Generic mfg.
Impact of the rate of radiographic response (RR) of brain metastases (BM) to whole brain radiation therapy (WBRT) on neurocognitive function (NCF) on NRG-CC001 (West/Central Hall) - Sep 28, 2022 - Abstract #SNO2022SNO_846;
CR or PR is associated with better NCF preservation. This suggests investigation into treatment escalation for patients with SD/PD may provide further NCF benefit along with HA-WBRT and memantine.Grant support from NCI-UG1CA189867 and U24CA180803.
- | modafinil / Generic mfg., memantine / Generic mfg., piracetam / Generic mfg.
Journal: Synthesis, Neuroprotective Effect and Physicochemical Studies of Novel Peptide and Nootropic Analogues of Alzheimer Disease Drug. (Pubmed Central) - Sep 24, 2022
The significative correlation equations relating the solubility and biological properties with the structural HYBOT (Hydrogen Bond Thermodynamics) descriptors were derived. These equations would greatly simplify the task of the directed design of the memantine analogues with improved solubility and enhanced bioavailability.
- | Omnicef (cefdinir) / Abbott
Journal: Sorption of cefdinir, memantine, praziquantel and trimethoprim in sediment and soil samples. (Pubmed Central) - Sep 24, 2022
The studied influence of pH showed a negative trend for memantine and trimetoprim, while an increase in ionic strength resulted in higher K values for all drugs. The sorption mechanism for all tested samples was best described by the pseudo-secondary kinetic model (R > 0.9999).
- | dizocilpine (MK801) / Merck (MSD)
Journal: Neuronal network-based biomimetic chip for long-term detection of olfactory dysfunction model in early-stage Alzheimer's disease. (Pubmed Central) - Sep 24, 2022
Moreover, MK-801 and memantine were administrated at early-stage to detect alteration of OB neurons simulating nasal administration for AD treatment, which showed an almost recovery through the intermittent firing pattern. Together, this neuronal network-on-chip has revealed synaptic impairment and network neurodegeneration of olfactory dysfunction in AD, providing potential mechanisms information for early-stage progressive olfactory amyloidogenic pathology.
- | amantadine / Generic mfg.
Journal: Novel Multipotent Amantadine-M30D Hybrids with Highly Selective Butyrylcholinesterase Inhibition and Neuroprotective Effects as Effective Anti-Alzheimer's Agents. (Pubmed Central) - Sep 24, 2022
Finally, the hit compound 5e exhibited in vitro blood-brain barrier (BBB) permeability and human plasma stability, as well as an optimal in silico neuropharmacokinetic profile. From a therapeutic perspective, merging key pharmacophoric features from memantine and M30D provides a new medicinal scaffold with dual-/multifunctional properties and human plasma stability for the future development of potential drugs for treating AD.
- clonazepam / Generic mfg., baclofen / Generic mfg., memantine / Generic mfg.
4 YEARLONG POST PARTUM AUTOIMMUNE CHOREA AS INITIAL PRESENTATION OF INCOMPLETE SLE/APS (Poster Station: 14) - Sep 22, 2022 - Abstract #MDSCongress2022MDR_Congress_468;
Postpartum stage may induce an exacerbation of autoimmune disease such as SLE. Neuropsychiatric SLE/APS manifestations include Autoimmune chorea and should be considered as an early in the diagnosis.
- | memantine / Generic mfg.
Journal: Förster resonance energy transfer-based kinase mutation phenotyping reveals an aberrant facilitation of Ca/calmodulin-dependent CaMKIIα activity in de novo mutations related to intellectual disability. (Pubmed Central) - Sep 21, 2022
Finally, the pharmacological reversal of CAMK2A P212L phenotype in neurons was demonstrated using an FDA-approved NMDA receptor antagonist memantine, providing a basis for targeted therapeutics in CAMK2A-linked intellectual disability. Taken together, FRET-based kinase mutation phenotyping sheds light on the biological impact of CAMK2A mutations and provides a selective, sensitive, quantitative, and scalable strategy for gaining novel insights into the molecular etiology of intellectual disability.
- ||| rivastigmine / Generic mfg.
Journal, Adverse events: Dysphagia Risk in Patients Prescribed Rivastigmine: A Systematic Analysis of FDA Adverse Event Reporting System. (Pubmed Central) - Sep 21, 2022
Patients prescribed rivastigmine were at greater risk of reporting dysphagia as an adverse event than patients prescribed many other medicines. This increase in dysphagia occurrence may be attributed to the dual inhibition of both acetylcholinesterase and butyrylcholinesterase.
- | memantine / Generic mfg.
Journal: Dichrocephala integrifolia Aqueous Extract Antagonises Chronic and Binges Ethanol Feeding-Induced Memory Dysfunctions: Insights into Antioxidant and Anti-Inflammatory Mechanisms. (Pubmed Central) - Sep 21, 2022
Dichrocephala integrifolia (100 and 200 mg/kg) likewise memantine (200 mg/kg) significantly (p < 0.01) alleviated ethanol-induced increase, in the brain malondialdehyde level, nitric oxide, Il-1β, TNF-α, and Il-6. From these findings, it can be concluded that Dichrocephala integrifolia counteracted memory impairment, oxidative stress, and neuroinflammation induced by chronic ethanol consumption in mice.
- || memantine / Generic mfg.
Review, Journal: Treatment Modalities for Dementia in Down's Syndrome: A Literature Review. (Pubmed Central) - Sep 20, 2022
The prevalence of dementia has increased as a function of the extended life expectancy of persons with DS. Because we know little about the treatment of dementia in persons with DS, this review focuses on the pathophysiology and management strategies to improve the overall quality of life.
- | Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma
Retrospective data, Journal: The Dose- and Duration-Dependent Association between Melatonin Treatment and Overall Cognition in Alzheimer's Dementia: A Network Meta-Analysis of Randomized Placebo-Controlled Trials. (Pubmed Central) - Sep 20, 2022
Because we know little about the treatment of dementia in persons with DS, this review focuses on the pathophysiology and management strategies to improve the overall quality of life. The current NMA provides evidence for the potential benefits of exogenous melatonin supplementation, especially medium-term low-dose melatonin, in participants with AD.
- || Nectiv (traxoprodil) / Pfizer
Review, Journal: N-methyl-D-aspartate receptor antagonists in improving cognitive deficits following traumatic brain injury: a systematic review. (Pubmed Central) - Sep 20, 2022
Although some benefits were observed, there are still some concerns regarding the efficacy and safety of NMDAR antagonists in improving post-TBI cognitive deficits. Further research is required to examine whether (i) these agents, notably amantadine, could accelerate cognitive improvement and shorten the hospital stay, (ii) these agents affect different cognitive domains/subdomains in the same direction, (iii) an optimal therapeutic time window exists, (iv) a member of this drug class can be proved to be effective without interfering in non-excitotoxic actions of glutamate, (v) they can be more effective as part of combination therapies or in particular subgroups of patients with TBI.
- Cognex (tacrine) / Shionogi
Dementia in Adults with Systemic Lupus Erythematosus 65 Years of Age and Above: A National Administrative Claims Data Analysis (Virtual Poster Hall) - Sep 17, 2022 - Abstract #ACRConvergence2022ACR_CONVERGENCE_2615;
In contrast to prior studies of non-US-based samples including primarily young and mid-aged adults, dementia prevalence was similar between older adults with SLE and non-SRD comparators in this US-based sample. Further study is underway to examine secular trends in dementia prevalence among aging US adults with and without SLE
- | memantine / Generic mfg.
New P2 trial: Efficacy of Chinese Traditional Medicine "Smart Soup" in Cognition and Behavior Regulation in Alzheimer's Disease (clinicaltrials.gov) - Sep 14, 2022
P2, N=180, Recruiting, Sponsor: Peking Union Medical College Hospital
- || memantine / Generic mfg.
Clinical, Journal: Memantine as treatment for compulsivity in child and adolescent psychiatry: Descriptive findings from an incompleted randomized, double-blind, placebo-controlled trial. (Pubmed Central) - Sep 14, 2022
P2
Our findings, although based on a very small number of patients and therefore insufficient to draw clear conclusions, appear to be in line with the hypothesis that memantine is an effective, tolerable and safe agent for children and adolescents. EudraCT Number: 2014-003080-38, Registered 14 July 2014, https://www.clinicaltrialsregister.eu/ctr-search/search?query=2014-003080-38.
- | riluzole / Generic mfg., memantine / Generic mfg., minocycline / Generic mfg.
Preclinical, Journal: Pharmacological Modulation of Glutamatergic and Neuroinflammatory Pathways in a Lafora Disease Mouse Model. (Pubmed Central) - Sep 14, 2022
A mouse model of Lafora disease (Epm2b-/-) was used to check the putative beneficial effect of different drugs aimed to ameliorate the alterations in glutamatergic transmission and/or neuroinflammation present in the model. Drugs in blue gave a more positive outcome than the rest.
- | memantine / Generic mfg., cimetidine / Generic mfg.
Preclinical, Journal: Targeting organic cation transporters at the blood-brain barrier to treat ischemic stroke in rats. (Pubmed Central) - Sep 12, 2022
All positive effects of memantine were attenuated by co-administration of cimetidine, which demonstrates that Oct1/Oct2 transport is required for memantine to exert neuroprotective effects in ischemic stroke. Furthermore, Oct1/Oct2-mediated transport was shown to be the dominant mechanism for memantine brain uptake in the MCAO model despite a concurrent increase in paracellular "leak." These novel and translational findings provide mechanistic evidence on the critical role of BBB transporters in CNS delivery of stroke therapeutics, information that can help such drugs advance in clinical trials.
- || memantine / Generic mfg.
Clinical, Journal: Favorable Response to "Memantine" in a Child with GRIN2B Epileptic Encephalopathy. (Pubmed Central) - Sep 10, 2022
The use of memantine along with antiepileptic drug polytherapy has proved to be beneficial in our case. Our experience with memantine and favorable outcome opens up the scope of more research into the use of NMDA receptor antagonist as a drug option for refractory epilepsies with proven genetic mutation and hence improves the overall neurodevelopmental outcome and survival chance.
- || memantine / Generic mfg.
Retrospective data, Review, Journal: Evaluation of memantine's efficacy and safety in the treatment of children with autism spectrum disorder: A systematic review and meta-analysis. (Pubmed Central) - Sep 10, 2022
However, memantine does not improve the core symptoms of autism. Nevertheless, further long-term trials are needed to explore its potential efficacy.
- | morphine sulphate / Generic mfg., quetiapine / Generic mfg.
Journal: Quetiapine attenuates the acquisition of morphine-induced conditioned place preference and reduces ERK phosphorylation in the hippocampus and cerebral cortex. (Pubmed Central) - Sep 10, 2022
Quetiapine attenuates morphine-induced CPP and locomotion and these effects are associated with a reduction of ERK phosphorylation in the hippocampus and cerebral cortex. These results suggest that quetiapine should be further explored as a potential treatment for opioid use disorder.
- || ketamine / Generic mfg., memantine / Generic mfg.
Review, Journal: Molecular mechanisms underlying the N-methyl-d-aspartate receptor antagonists: Highlighting their potential for transdiagnostic therapeutics. (Pubmed Central) - Sep 10, 2022
Despite longstanding concerns about side effects of NMDAR antagonists, recent research suggests that, when appropriately used, these agents have favourable safety profiles. Furthermore, their fast-acting mechanism of action, resulting in rapid effects compared to other therapeutic agents, makes them a promising class of drugs that may yield effective therapeutics for multiple CNS disorders.
- | memantine / Generic mfg.
Preclinical, Journal: Suppression of exaggerated NMDAR activity by memantine treatment ameliorates neurological and behavioral deficits in aminopeptidase P1-deficient mice. (Pubmed Central) - Sep 10, 2022
In addition, abnormally enhanced NMDAR-dependent LTP and NMDAR downstream signaling in the hippocampi of Xpnpep1 mice were reversed by chronic memantine treatment. These results suggest that the metabolic dysfunction caused by aminopeptidase P1 deficiency leads to synaptic dysfunction with excessive NMDAR activity, and the restoration of synaptic function may be a potential therapeutic strategy for the treatment of neurological complications related to IEMs.
- | memantine / Generic mfg.
Journal: Memantine has a nicotinic neuroprotective pathway in acute hippocampal slices after an NMDA insult. (Pubmed Central) - Sep 10, 2022
In conclusion, our studies show memantine is neuroprotective through a nicotinic pathway, similar to the nicotinic drug 4R. This information leads to a better understanding of memantine's mechanisms of action and explains its dose-dependent effectiveness in Alzheimer's and other neurological disorders.
- | memantine / Generic mfg.
Journal: A 6-month trial of memantine for nystagmus and associated phenomena in oculopalatal tremor. (Pubmed Central) - Sep 7, 2022
The long-term use of memantine 20 mg per day in OPT produced a modest and only transient improvement in nystagmus, predominantly along the horizontal plane. Visual acuity improved, albeit without relevant changes in vision-related quality of life.
- | memantine / Generic mfg.
Journal: The neurophysiological effect of NMDA-R antagonism of frontotemporal lobar degeneration is conditional on individual GABA concentration. (Pubmed Central) - Sep 5, 2022
Both magnetoencephalography sessions recorded a roving auditory oddball paradigm: on placebo or following 10 mg memantine, an uncompetitive NMDA-receptor antagonist...This proof-of-concept study demonstrates the potential for baseline dependency in the pharmacological restoration of neurotransmitter deficits to influence cognitive neurophysiology in neurodegenerative disease. With changes to multiple neurotransmitters in frontotemporal lobar degeneration, we suggest that individuals' balance of excitation and inhibition may determine drug efficacy, with implications for drug selection and patient stratification in future clinical trials.
- galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Alzheimer's Disease Occurs More Frequently in Patients With Celiac Disease: A Nationwide Population-Based Cohort Study (Crown Ballroom) - Sep 4, 2022 - Abstract #ACG2022ACG_865;
Among CD patients, 970 (1.1%) carried an AD diagnosis compared to 194,030 (0.8%) of the non-CD patients (p < 0.0001). After multivariate analysis, CD was associated with increased odds of Alzheimer’s disease (aOR = 5.38, 95% CI = 5.30-5.45, p < 0.0001) (Figure 1).
- || Aduhelm (aducanumab) / Eisai, Biogen, Nine Phase One (mannote sodium) / Shanghai Greenvalley
Review, Journal: Symptomatic and Disease-Modifying Therapy Pipeline for Alzheimer's Disease: Towards a Personalized Polypharmacology Patient-Centered Approach. (Pubmed Central) - Sep 3, 2022
Small molecules, mAbs, or multimodal strategies showing promise in animal studies have not confirmed that promise in the clinic (where small to moderate changes in clinical efficacy have been observed), and therefore, there is a significant unmet need for a better understanding of the AD pathogenesis and the exploration of alternative etiologies and therapeutic effective disease-modifying therapies strategies for AD. Therefore, a critical review of the disease-modifying therapy pipeline for Alzheimer's disease is needed.
- || memantine / Generic mfg.
Review, Journal: Memantine for autism spectrum disorder. (Pubmed Central) - Sep 2, 2022
None of the three included trials reported on the effectiveness of memantine in adults. Further studies using rigorous designs, larger samples, longer follow-up and clinically meaningful outcome measures that are important to autistic people and their families will strengthen our knowledge of the effects of memantine in autism.
- An Evaluation of Health Technology Assessment (HTA) Requirements for Emerging Therapies in Alzheimer’s Disease (AD) (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_756;
Then we mapped the identified requirements from the HTA reports with endpoints used in clinical trials of emerging therapies (identified through clinicaltrials.gov), namely aducanumab, donanemab, gantenerumab, and lecanemab...Donepezil, galantamine, rivastigmine, and memantine are reimbursed in Germany, England, and Wales but not in France... Although clinical trials on new AD agents include HTA- and payer-relevant endpoints, it is highly recommended to also assess time to institutionalisation, HRQoL, and caregiver burden to generate a compelling HTA and payer evidence package.
- memantine / Generic mfg.
Evaluation of Cost by TPS vs Pharmacotherapy of Dementia in Ukraine (Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_497;
Memantine... Estimated of cost on treatment for dementia in Ukraine can be reduced by 90.2% while using the cheapest generics.
- Aduhelm (aducanumab) / Eisai, Biogen
The Challenge of Demonstrating Cost Effectiveness in Alzheimer's Disease in England: Case Study of a Hypothetical Emerging Treatment (In-person; Virtual) - Sep 1, 2022 - Abstract #ISPOREU2022ISPOR_EU_387;
The analysis suggests that a commercial arrangement would likely be required for a HET to be considered cost-effective from an English NHS perspective. Drivers of cost effectiveness in this AD analysis were found to be consistent with those detailed in literature.
- | memantine / Generic mfg.
Journal: Chromone derivatives suppress neuroinflammation and improve mitochondrial function in the sporadic form of Alzheimer's disease under experimental conditions. (Pubmed Central) - Aug 30, 2022
Moreover, in terms of the effect on changes in the activity of mitochondrial enzymes and aerobic metabolism, these substances significantly exceeded memantine. The study showed that from the analyzed chromone derivatives, two compounds C3AACP6 and C3AACP7 could have a neuroprotective effect in Alzheimer's disease, which is realized through the axis: recovery of mitochondrial function, decrease extramitochondrial cardiolipin, decrease neuroinflammation, neuroprotection.
- | Journal: Drugs for cognitive loss and dementia. (Pubmed Central) - Aug 28, 2022
The study showed that from the analyzed chromone derivatives, two compounds C3AACP6 and C3AACP7 could have a neuroprotective effect in Alzheimer's disease, which is realized through the axis: recovery of mitochondrial function, decrease extramitochondrial cardiolipin, decrease neuroinflammation, neuroprotection. No abstract available
- | Aduhelm (aducanumab) / Eisai, Biogen, Namzaric (memantine ER/donepezil) / AbbVie, Supernus Pharma, Adlarity (donepezil transdermal system) / Corium
Journal: Comparison table: Drugs for Alzheimer's disease. (Pubmed Central) - Aug 28, 2022
No abstract available No abstract available
- | dextromethadone (REL-1017) / Relmada Therapeutics
Journal: Pharmacological Comparative Characterization of REL-1017 (Esmethadone-HCl) and Other NMDAR Channel Blockers in Human Heterodimeric N-Methyl-D-Aspartate Receptors. (Pubmed Central) - Aug 27, 2022
In silico studies of NMDARs in closed and open conformation indicate that REL-1017 has a higher preference for docking and undocking the open-channel conformation compared to ketamine. In conclusion, the pharmacological characteristics of REL-1017 at NMDARs, including relatively low affinity at the NMDAR, NR1-2D subtype preference in the presence of 1 mM Mg, tau off and degree of trapping similar to (±)-ketamine, and preferential docking and undocking of the open NMDAR, could all be important variables for understanding the rapid-onset antidepressant effects of REL-1017 without psychotomimetic side effects.
- || memantine / Generic mfg.
Retrospective data, Review, Journal: Postamputation Residual Limb Pain Severity and Prevalence: A Systematic Review and Meta-Analysis. (Pubmed Central) - Aug 24, 2022
The most severe pain is reported by patients undergoing amputations due to cancer, followed by traumatic amputations, while vascular amputation patients report lower pain severity. Promising methods of reducing long-term pain are preoperative pain control, nerve or epidural blocks, use of memantine, calcitonin-containing blocks, and prophylactic nerve coaptations.
- | memantine / Generic mfg.
Journal: Memantine ameliorates the impairment of social behaviors induced by a single social defeat stress as juveniles. (Pubmed Central) - Aug 22, 2022
These findings suggest that memantine ameliorates social behavioral impairment in mice exposed to a single social defeat stress as juveniles by regulating the NMDA receptor and subsequent ERK1/2 signaling activation. Memantine may constitute a novel therapeutic drug for stress-related psychiatric disorders in juveniles with adverse juvenile experiences.
- || galantamine hydrobromide / Generic mfg., memantine / Generic mfg., rivastigmine / Generic mfg.
Review, Journal: Advances on Therapeutic Strategies for Alzheimer's Disease: From Medicinal Plant to Nanotechnology. (Pubmed Central) - Aug 22, 2022
We have discussed pathophysiology, various targets, FDA-approved drugs, and various drugs in clinical trials against AD. The goal of this study is to shed light on current developments and treatment options, utilizing phytopharmaceuticals, nanomedicines, nutraceuticals, and gene therapy.
- | memantine / Generic mfg.
Journal: Novel effective small-molecule inhibitors of protein kinases related to tau pathology in Alzheimer's disease. (Pubmed Central) - Aug 18, 2022
Background: Alzheimer's disease (AD) drugs in therapy are limited to acetylcholine esterase inhibitors and memantine...Best results in nanomolar ranges were found for benzopyridofuranes with a 6-hydroxy and a 3-alkoxy substitution or an exclusive 6-alkoxy substituent. First lead compounds were identified inhibiting two to three kinases in nanomolar ranges to be qualified as an innovative approach for AD multitargeting.